• Sara Jane Cromer, Kristin M D'Silva, Elaine W Yu, Joan Landon, Rishi J Desai, and Seoyoung C Kim.
• Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.
• J Gen Intern Med. 2022 Jun 1; 37 (8): 191719241917-1924.

BackgroundNew bone-directed therapies, including denosumab, abaloparatide, and romosozumab, emerged during the past decade, and recent trends in use of these therapies are unknown.ObjectiveTo examine temporal trends in bone-directed therapies.DesignAn open cohort study in a US commercial insurance database, January 2009 to March 2020.Participants/InterventionsAll-users of bone-directed therapies age >50 years, users with osteoporosis, users with malignancies, and patients with recent (within 180 days) fractures at key osteoporotic sites.Main MeasuresThe percentage of each cohort with prescription dispensing or medication administration claims for each bone-directed therapy during each quarter of the study period.Key ResultsWe analyzed 15.48 million prescription dispensings or medication administration claims from 1.46 million unique individuals (89% women, mean age 69 years). Among all users of bone-directed therapies, alendronate, and zoledronic acid use increased modestly (49 to 63% and 2 to 4%, respectively, during the study period). In contrast, denosumab use increased rapidly after approval in 2010, overtaking use of all other medications except alendronate by 2017 and reaching 16% of users by March 2020. Similar trends were seen in cohorts of osteoporosis, malignancy, and recent fractures. Importantly, use of any bone-directed therapy after fractures was low and declined from 15 to 8%.ConclusionsRates of denosumab use outpaced growth of all other bone-directed therapies over the past decade. Treatment rates after osteoporotic fractures were low and declined over time, highlighting major failings in osteoporosis treatment in the US.© 2021. Society of General Internal Medicine.

26 keywords...

hide…